Introduction
In early breast cancer, surgery is the mainstay of curative treatment. Complementary local (radiotherapy) and systemic (adjuvant endocrine therapy or chemotherapy) treatments are associated with the aim of reducing the risk of relapse according to the clinicopathological characteristics of the tumor. However, the possibility of administering these therapies prior to surgery (neoadjuvant setting) offers several advantages: reduction in tumor size to improve respectability, an increased rate of conservative surgery improving esthetic results, reduction in the extent of axillary surgery, and early treatment of micrometastatic disease.
Two main clinical trials have compared the administration of chemotherapy before or after surgery in operable breast cancer, NSABP B-18 [1] and NSABP B-27 [2, 3] . Both demonstrate that preoperative therapy is equivalent to adjuvant therapy in the shortand long-term outcomes. B-27 also showed that the addition of preoperative taxanes to anthracyclines improves response. The design and results of these studies are detailed in table 1. from both breast and lymph nodes (ypT0 ypN0 or ypTis ypN0) as this is better associated with improved event-free survival (EFS) and overall survival (OS) than other prior pCR definitions (tumor eradication from breast only ypT0).
Furthermore, the association with better long-term outcomes is stronger in more aggressive tumor types (triple-negative, HER2-positive/hormone receptor(HR)-negative, high-grade HR-positive).
Another parameter that provides us with information about tumor behavior is the RCB, a value calculated from the residual tumor characteristics and which grades the pathological response from 0 (without residual disease) to III (extensive residual disease). It is an independent prognostic factor that also correlates with disease-free survival (DFS) by breast cancer subtype in a similar manner as pCR [8] .
Endocrine Therapy
Several studies have attempted to explore the role of hormonal therapy in the setting of neoadjuvant treatment of breast cancer. As the response of luminal tumors to endocrine treatment is biologically different, it is reasonable to employ an alternative parameter to pCR that evaluates the response to treatment and its correlation with prognosis. This tool is the preoperative endocrine prognostic index (PEPI) that provides a score based on the sum of risk points derived from pT stage, pN stage, ki67 level, and estrogen receptor (ER) status of the surgical specimen. The PEPI score provides a prognostic value to aid the decision regarding subsequent adjuvant treatment [9] .
On the other hand, it is important to highlight the information obtained from the reduction in the expression of the proliferation antigen Ki-67 during hormonal treatment as a response marker and as a surrogate prognostic marker, when compared with Ki-67 at baseline. A subanalysis of 158 patients from the IMPACT trial observed that a high Ki-67 value after 2 weeks of endocrine therapy was correlated with a worse recurrence-free survival, while higher Ki-67 expression at baseline was not [10] . These data suggest that the measurement of changes in Ki-67 after neoadjuvant therapy is a better predictor of prognosis than the baseline value.
This hypothesis was confirmed in a recent study (POETIC trial [11] ) with a larger number of patients (n = 4,480) in whom ki67 was measured at baseline and after 2 weeks of neoadjuvant endocrine therapy; both results were stratified into low (<10%) or high (>10%) expression. Low Ki-67 at baseline was correlated with a better prognosis and no need for other systemic treatment. In contrast, a high Ki-67 value after 2 weeks of hormonal treatment was found to be a bad prognostic factor suggesting the need for adjuvant chemotherapy. However, baseline Ki-67 is not a good indicator to identify luminal subtype (LumA/LumB) because of the low correlation with PAM50 intrinsic subtypes (3.3% HER2-enriched and basal-like) [12] .
Tamoxifen versus Aromatase Inhibitors
Greater responses in terms of breast-conserving surgery (BCS) are obtained with aromatase inhibitors (AI) versus tamoxifen in postmenopausal women with ER-positive/HER2-negative breast cancer (table 2) [13] . However, no statistically significant differences were found when exemestane, letrozol, and anastrozole were compared [12] , obtaining a clinical response rate higher than 60% with all 3 AI. After these results, on the basis of slightly higher clinical response rates, letrozole and anastrozole were selected for further investigation, and no other differences in surgical outcome, PEPI score, or Ki-67 suppression were detected. The BCS rate for mastectomy candidates at diagnosis was 51%.
Regarding the optimal duration of endocrine neoadjuvant therapy, in all previous studies, treatment was administered for approximately 4 months (12-16 weeks) with an interim analysis of Ki-67 at 2-4 weeks to check response. In terms of effectiveness, a greater benefit in biological parameters was observed in LumA subtypes according to PAM50 [12] , and no responses were detected in the non-luminal subtypes (3.3%). In a small subgroup of LumA patients, a Ki-67 increase was observed that seems to be related to hormone resistance mechanisms.
With these data, best candidates for endocrine neoadjuvant therapy will be those who are postmenopausal with an intrinsic LumA subtype, elderly, or unfit for chemotherapy.
In the ACOSOG trial [12] , the subgroup with Ki-67 > 10% after 2 weeks of endocrine therapy had worse recurrence-free survival despite the fact that most patients (71%) completed neoadjuvant chemotherapy.
Chemotherapy and Antiangiogenic Agents
Chemotherapy, given with anti-HER2-targeted drugs in the case of HER2-positive disease, is the standard neoadjuvant approach. Commonly used regimens for patients with HER2-negative disease, especially in the higher-risk category, include anthracycline-based regimens such as doxorubicin and cyclophosphamide followed or proceeded by a taxane (docetaxel or paclitaxel). For those in whom the potential cardiotoxic effects of anthracyclines are a primary concern, non-anthracycline regimens are a reasonable alternative [14] .
Anthracycline-Based Regimens
The rationale for the use of anthracyclines and taxanes in the preoperative setting comes directly from clinical trials of neoadjuvant treatment [15] . Specifically in the neoadjuvant setting, multiple studies have demonstrated that the addition of a taxane to an anthracycline-based regimen, either concurrently or sequentially, is associated with increased response rates (table 1) .
Neoadjuvant Carboplatin and Bevacizumab
The hypothesis of an increased efficacy of platinum agents in triple-negative breast cancer (TNBC) is based on the fact that these tumors often show functional DNA repair alterations that increase the sensitivity to cross-linking agents [16] .
The phase II GeparSixto trial [16] explored the impact of the addition of carboplatin to neoadjuvant chemotherapy based in anthracyclines and taxanes. 595 patients with previously untreated, non-metastatic, stage II-III TNBC and HER2-positive breast cancer were enrolled. Patients were treated with concurrent weekly paclitaxel and weekly non-pegylated liposomal doxorubicin. Patients with TNBC received simultaneous bevacizumab, and patients with HER2-positive disease received simultaneous trastuzumab and lapatinib. Patients were randomly assigned at a 1: 1 ratio to receive concurrent carboplatin or not. 43.7 versus 36.9% achieved a pCR, favoring treatment with carboplatin. However, this regimen seems to significantly increase responses in patients with TNBC (53.2 vs. 36.9%; p = 0.005), but not in those with HER2-positive disease (32.8 vs. 36.8%; p = 0.581).
The phase II trial CALGB 40603 (Alliance) [17] explored the combination of carboplatin and/or bevacizumab with neoadjuvant chemotherapy. 443 patients with stage II-III TNBC received weekly paclitaxel followed by doxorubicin plus cyclophosphamide every 2 weeks (ddAC), and were randomly assigned to concurrent carboplatin and/or bevacizumab (in a 2×2 factorial design).
Only the addition of carboplatin (54 vs. 41%; p = 0.0029) significantly raised pCR (defined as ypT0/is ypN0). The increase in the pCR breast/axilla rate with bevacizumab (52 vs. 44%) did not achieve statistical significance (p = 0.057). Again, patients who received both agents had the highest pCR rate (60%) with no significant interaction between their effects (p = 0.43). More-than-additive interactions between the 2 agents could not be demonstrated.
Patients assigned to either carboplatin or bevacizumab were less likely to complete weekly paclitaxel and ddAC without skipped doses, dose modification, or early discontinuation resulting from toxicity.
The phase III NSABP-40 trial [18] explored the addition of bevacizumab. This trial had a 3×2 factorial design, and enrolled patients with operable, HER2-non-amplified breast cancer, clinical stage T1c-3, cN0, cN1, or cN2a. Patients received 1 of 3 docetaxelbased neoadjuvant regimens: docetaxel alone, docetaxel plus capecitabine, or docetaxel plus gemcitabine. These 3 taxane arms were followed by neoadjuvant doxorubicin and cyclophosphamide. Those groups were randomly assigned (1: 1:1: 1:1: 1) to receive bevacizumab (neoadjuvant and adjuvant settings) versus not.
The addition of capecitabine or gemcitabine to docetaxel therapy, as compared with docetaxel therapy alone, did not significantly increase the rate of pCR (23.2 and 26.9% vs. 25.8%; p = 0.51), and both were associated with increased toxicity. The addition of bevacizumab did not significantly increase the rate of pCR (defined as ypT0 ypN0) (27.6 vs. 23%; p = 0.08).
The addition of carboplatin increased hematologic and non-hematologic toxicity, with subsequent dose reductions and discontinuations (48% with carboplatin and 39% without carboplatin; p = 0.031) [18] . Hematologic and non-hematologic toxic effects were significantly more common in the carboplatin group than in the no-carboplatin group. This increased toxicity and the lack of clear long-term survival benefits are the main reasons why the use of platinum agents is controversial as standard care for TNBC. In spite of this, the evidence that pCR is strongly associated with OS in TNBC is an argument often used by physicians to justify the addition of carboplatin to neoadjuvant systemic treatment in clinical practice. Several phase III trials are ongoing and may provide more information on this topic.
The use of bevacizumab in the neoadjuvant setting is still controversial and is not recommended, mainly due to the lack of survival benefit evidence and the increase in toxicity.
Neoadjuvant Nab-Paclitaxel
In the phase III GeparSepto trial [19] , 1,026 patients (396 HER2-positive, 276 triple-negative, and 534 HR-positive/HER2-negative) with previously untreated unilateral or bilateral breast cancer were randomized 1: 1 to receive weekly nab-paclitaxel 150 mg/m 2 (after study amendment 125 mg/m 2 due to the higher incidence of severe sensory neuropathy) or conventional paclitaxel (80 mg/m 2 [2] weekly), followed by epirubicin plus cyclophosphamide. Patients with HER2-positive tumors received concurrent trastuzumab and pertuzumab.
pCR was higher in the nab-paclitaxel group (38%) than in the paclitaxel group (29%) (p = 0.00065). In the efficacy analysis by subgroup, significant differences were observed in the TNBC subtype (48 vs. 26%; p = 0.00027). No significant differences were observed either in patients with HER2-positive tumors (62 vs. 54%; p = 0.13) or in those with HER2-negative/HR-positive disease (16 vs. 12%; p = 0.23). However, in the HER2-negative/HR-positive group, a benefit in terms of DFS after a median follow-up of 4 years (hazard ratio 0.71; p = 0.660) was observed, similar to the benefit in the TNBC group (hazard ratio 0.66; p = 0.0694) [20] .
Neoadjuvant Nab-Paclitaxel Combined with Carboplatin
In the WSG-ADAPT-TN trial [21] , 336 TNBC patients were randomly assigned to nab-paclitaxel plus gemcitabine (arm A) versus nab-paclitaxel plus carboplatin (arm B), in an anthracyclinefree regimen. pCR favored arm B (28.7 vs. 45.9%; p = 0.002), which shows the high efficacy and excellent tolerability of a neoadjuvant nab-paclitaxel plus carboplatin regimen in TNBC. The authors concluded that the de-escalation of further chemotherapy in patients with early pCR after a short anthracycline-free regimen is a promising field of future research (table 3) .
Anti-HER2 Agents
Neoadjuvant Trastuzumab Molecular targeting of the HER2 receptor with the humanized monoclonal antibody trastuzumab improved DFS and OS in patients with both metastatic and early HER2-positive breast cancer [22] .
The phase III NOAH trial [23] explored the addition of trastuzumab to neoadjuvant chemotherapy. 235 patients with HER2-positive locally advanced or inflammatory breast cancer were randomly assigned 1: 1 to receive chemotherapy alone (consisting of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and fluorouracil) or with 1 year of trastuzumab (concurrently with neoadjuvant chemotherapy and continued after surgery). A parallel cohort of 99 patients with HER2-negative disease was included and treated with the same chemotherapy regimen.
The rate of pCR was 19% in the arm without trastuzumab and 38% in the arm with trastuzumab (p = 0.001). The rate of pCR in the HER2-negative arm was 16%.
The 5-year EFS was 58% (95% confidence interval (CI) 48-66) in the trastuzumab group and 43% (95% CI 34-52) in the chemotherapy group (hazard ratio 0.64, 95% CI 0.44-0.93; two-sided logrank p = 0.016). EFS was strongly associated with pCR in patients who received trastuzumab. Of the 68 patients with a pCR, the hazard ratio for EFS between those with and without trastuzumab was 0.29 (95% CI 0.11-0.78). Results showing improved survival in the trastuzumab group were not significant in this trial, probably be- cause of a crossover to adjuvant trastuzumab in 17% of patients and the use of trastuzumab at relapse. The phase III Z1041 trial [24] explored the concurrent administration of trastuzumab with anthracyclines. 282 patients with HER2-positive breast cancer were randomly assigned (1: 1) to sequential treatment (5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by weekly paclitaxel and trastuzumab) or to concurrent treatment (paclitaxel and trastuzumab followed by FEC-75 and weekly trastuzumab). There was not additional benefit of the concurrent treatment in terms of pCR (defined in this trial as ypT0; 56.6 vs. 54.2%).
Dual Blockade with Trastuzumab plus Lapatinib
In the phase III GeparQuinto trial [25] , 620 patients with untreated HER2-positive operable or locally advanced breast cancer were randomly assigned at a 1: 1 ratio to receive neoadjuvant treatment with epirubicin plus cyclophosphamide followed by docetaxel, with either trastuzumab or lapatinib. Patients completed post-surgery trastuzumab treatment for 1 year in both treatment groups. The rate of pCR was lower in the lapatinib arm (22.7 vs. 30.3% in the trastuzumab arm), and the authors concluded that lapatinib should not be used outside of clinical trials as single anti-HER2 treatment in combination with neoadjuvant chemotherapy.
In the phase II NeoAltto trial [26] , 529 patients with operable HER2-positive tumors were randomly assigned 1: 1:1 to lapatinib, trastuzumab, or lapatinib plus trastuzumab for 6 weeks, followed by an additional 12 weeks of the assigned anti-HER2 therapy in combination with weekly paclitaxel (80 mg/m²). After surgery, women received FEC followed by 34 weeks of the same assigned neoadjuvant anti-HER2 therapy. pCR (breast and axilla) was achieved in 20% of the patients in the lapatinib arm, 27.6% in the trastuzumab arm (p = 0.13), and 46.8% in the combination group (p = 0.0007). However, lapatinib plus trastuzumab did not significantly improve DFS compared with trastuzumab alone (hazard ratio 0.84, 97.5% CI 0.70-1.02; p = 0.048 (p 0.025 required for statistical significance to adjust for multiple testing). Additionally, this combination has a higher rate of toxicities (such as diarrhea, rash, and hepatic toxicity) and a higher rate of interruption of the neoadjuvant treatment due to adverse events.
Dual Blockage with Trastuzumab plus Pertuzumab
In the phase II NeoSphere trial [27] , 417 patients with operable, locally advanced or inflammatory HER2-positive breast cancer were randomly assigned 1: 1:1: 1 to receive 4 neoadjuvant cycles of: trastuzumab plus docetaxel (group A) or pertuzumab and trastuzumab plus docetaxel (group B) or pertuzumab and trastuzumab (group C) or pertuzumab plus docetaxel (group D). Patients given pertuzumab and trastuzumab plus docetaxel (group B) had a significantly improved pCR rate (45.8%) compared with those given trastuzumab plus docetaxel (group A, 29%). 24% women given pertuzumab plus docetaxel (group D) had a pCR, as did 16.8% given pertuzumab and trastuzumab (group C).
In the phase II TRYPHAENA trial [28] , designed as a cardiosecurity study, 225 patients with operable, locally advanced, or inflammatory breast cancer were randomized 1: 1:1 to receive 6 neoadjuvant cycles (Arm A: FEC + trastuzumab + pertuzumab ×3 docetaxel + trastuzumab + pertuzumab ×3; Arm B: FEC ×3 docetaxel + trastuzumab + pertuzumab ×3; Arm C: docetaxel + carboplatin + trastuzumab + pertuzumab ×6). Adjuvant therapy was given to complete 1 year of trastuzumab. pCR (defined as ypT0 ypN0) was achieved in 50.7% (Arm A), 45.3% (Arm B), and 51.9% (Arm C) of patients. The pCR rate was higher in patients with HRnegative tumors compared with patients with HR-positive tumors.
These results strongly support the use of dual-HER2 blockade for neoadjuvant treatment of HER2-positive breast cancer patients. The combination of chemotherapy plus trastuzumab and pertuzumab had the highest probability of being the best treatment in terms of pCR, although there are no direct comparisons. The im- pact of the pCR [29] in HER2 tumors in terms of EFS is clear (hazard ratio 0.49, 95% CI 0.33-0.71), and this association was greater for patients with HR-negative disease (hazard ratio 0.29, 95% CI 0.24-0.36) (table 4) .
Conclusion
Neoadjuvant treatment is the best approach in locally advanced tumors and in early stages of HER2-positive disease and TNBC. The pCR has an important role as a prognostic factor in these subtypes of breast cancer. The standard neoadjuvant treatment is chemotherapy based on anthracyclines and taxanes. In TNBC, the addition of carboplatin and substitution of paclitaxel by nab-paclitaxel should be considered, although it is currently controversial. In HER2-positive tumors, the standard treatment is dual blockage with trastuzumab and pertuzumab combined with chemotherapy (with or without anthracyclines). In selected HR-positive/HER2-negative tumors in postmenopausal women, hormone therapy with an AI could be another option, and the reduction in the expression of Ki-67 during hormonal treatment is a surrogate prognostic marker.
Disclosure Statement
The authors have no relationships to disclose.
